{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:30:38Z","timestamp":1793035838333,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/nrrheum.2017.126","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T04:19:56Z","timestamp":1502338796000},"page":"561-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)"],"prefix":"10.1038","volume":"13","author":[{"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Saag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"BFnrrheum2017126_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem, A., Harris, R. P. & Forciea, M. A. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 166, 58\u201368 (2017).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2017126_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 64, 1431\u20131446 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2017126_CR3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. (Hoboken) 64, 1447\u20131461 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2017126_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera, F. et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Ann. Rheum. Dis. 73, 328\u2013335 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/art.1780150209","volume":"15","author":"JN Loeb","year":"1972","unstructured":"Loeb, J. N. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 15, 189\u2013192 (1972).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12891-015-0762-4","volume":"16","author":"A Chhana","year":"2015","unstructured":"Chhana, A., Lee, G. & Dalbeth, N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord. 16, 296 (2015).","journal-title":"BMC Musculoskelet Disord."},{"key":"BFnrrheum2017126_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/art.1780130408","volume":"13","author":"DJ McCarty","year":"1970","unstructured":"McCarty, D. J. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum. 13, 414\u2013418 (1970).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","volume":"54","author":"DJ McCarty","year":"1961","unstructured":"McCarty, D. J. & Hollander, J. L. Identification of urate crystals in gouty synovial fluid. Ann. Intern. Med. 54, 452\u2013460 (1961).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2017126_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(62)90501-9","volume":"2","author":"JS Faires","year":"1962","unstructured":"Faires, J. S. & McCarty, D. J. Acute arthritis in man and dog after intra-synovial injection of sodium urate crystals. Lancet 2, 682\u2013685 (1962).","journal-title":"Lancet"},{"key":"BFnrrheum2017126_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/art.1780180722","volume":"18","author":"HR Schumacher","year":"1975","unstructured":"Schumacher, H. R. Pathology of the synovial membrane in gout. Light and electron microscopic studies. Interpretation of crystals in electron micrographs. Arthritis Rheum. 18, 771\u2013782 (1975).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR12","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.27356","volume":"62","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth, N. et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 62, 1549\u20131556 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/ard.2008.099713","volume":"68","author":"HK Choi","year":"2009","unstructured":"Choi, H. K. et al. Dual energy computed tomography in tophaceous gout. Ann. Rheum. Dis. 68, 1609\u20131612 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2125.1987.tb03132.x","volume":"24","author":"N Bellamy","year":"1987","unstructured":"Bellamy, N., Downie, W. W. & Buchanan, W. W. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br. J. Clin. Pharmacol. 24, 33\u201336 (1987).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrrheum2017126_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna, P. P. et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual. Life Outcomes 10, 117 (2012).","journal-title":"Health Qual. Life Outcomes"},{"key":"BFnrrheum2017126_CR16","doi-asserted-by":"publisher","first-page":"R132","DOI":"10.1186\/ar4589","volume":"16","author":"JA Singh","year":"2014","unstructured":"Singh, J. A. The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Res. Ther. 16, R132 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2017126_CR17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/RHU.0000000000000127","volume":"20","author":"O Aati","year":"2014","unstructured":"Aati, O., Taylor, W. J., Horne, A. & Dalbeth, N. Toward development of a Tophus Impact Questionnaire: a qualitative study exploring the experience of people with tophaceous gout. J. Clin. Rheumatol 20, 251\u2013255 (2014).","journal-title":"J. Clin. Rheumatol"},{"key":"BFnrrheum2017126_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/ard.2008.094201","volume":"68","author":"N Dalbeth","year":"2009","unstructured":"Dalbeth, N. et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann. Rheum. Dis. 68, 1290\u20131295 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jama.1941.02820060001001","volume":"116","author":"PS Hench","year":"1941","unstructured":"Hench, P. S. Diagnosis and treatment of gout and gouty arthritis. JAMA 116, 453\u2013455 (1941).","journal-title":"JAMA"},{"key":"BFnrrheum2017126_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/art.1780160402","volume":"16","author":"AB Gutman","year":"1973","unstructured":"Gutman, A. B. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum. 16, 431\u2013445 (1973).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR21","first-page":"577","volume":"28","author":"J Li-Yu","year":"2001","unstructured":"Li-Yu, J. et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol 28, 577\u2013580 (2001).","journal-title":"J. Rheumatol"},{"key":"BFnrrheum2017126_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/ard.2006.060368","volume":"66","author":"E Pascual","year":"2007","unstructured":"Pascual, E. & Sivera, F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann. Rheum. Dis. 66, 1056\u20131058 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/art.1780080431","volume":"8","author":"JE Seegmiller","year":"1965","unstructured":"Seegmiller, J. E. The acute attack of gouty arthritis. Arthritis Rheum. 8, 714\u2013725 (1965).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0022-0248(81)90068-3","volume":"53","author":"CY Lam Erwin","year":"1981","unstructured":"Lam Erwin, C. Y. & Nancollas, G. H. The crystallization and dissolution of sodium urate. J. Cryst. Growth 53, 215\u2013223 (1981).","journal-title":"J. Cryst. Growth"},{"key":"BFnrrheum2017126_CR25","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz, F., Martin, I. & Canteli, B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J. Rheumatol 34, 1888\u20131893 (2007).","journal-title":"J. Rheumatol"},{"key":"BFnrrheum2017126_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero-Beites, A. M. & Ruibal, A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356\u2013360 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker, M. A., Schumacher, H. R., MacDonald, P. A., Lloyd, E. & Lademacher, C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J. Rheumatol 36, 1273\u20131282 (2009).","journal-title":"J. Rheumatol"},{"key":"BFnrrheum2017126_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher","year":"2009","unstructured":"Schumacher, H. R. et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48, 188\u2013194 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2017126_CR29","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker, M. A. et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann. Rheum. Dis. 72, 1469\u20131474 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR30","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HS Baraf","year":"2013","unstructured":"Baraf, H. S. et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res. Ther. 15, R137 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2017126_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/acr.22059","volume":"66","author":"N Dalbeth","year":"2014","unstructured":"Dalbeth, N., Doyle, A. J., McQueen, F. M., Sundy, J. & Baraf, H. S. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy. Arthritis Care Res. (Hoboken) 66, 82\u201385 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2017126_CR32","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp, L. K. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 64, 2529\u20132536 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR33","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung, S. I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134\u20134139 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2017126_CR34","doi-asserted-by":"publisher","first-page":"h4848","DOI":"10.1136\/bmj.h4848","volume":"351","author":"TM Ko","year":"2015","unstructured":"Ko, T. M. et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 351, h4848 (2015).","journal-title":"BMJ"},{"key":"BFnrrheum2017126_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.7326\/0003-4819-153-3-201008030-00010","volume":"153","author":"A Qaseem","year":"2010","unstructured":"Qaseem, A., Snow, V., Owens, D. K. & Shekelle, P. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann. Intern. Med. 153, 194\u2013199 (2010).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2017126_CR36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees, F., Jenkins, W. & Doherty, M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann. Rheum. Dis. 72, 826\u2013830 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette, P., Clerson, P., Perissin, L., Flipo, R. M. & Bardin, T. Revisiting comorbidities in gout: a cluster analysis. Ann. Rheum. Dis. 74, 142\u2013147 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000045783","volume":"86","author":"F Perez-Ruiz","year":"2000","unstructured":"Perez-Ruiz, F., Calabozo, M., Herrero-Beites, A. M., Garcia-Erauskin, G. & Pijoan, J. I. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 86, 287\u2013291 (2000).","journal-title":"Nephron"},{"key":"BFnrrheum2017126_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"CF Kuo","year":"2016","unstructured":"Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann. Rheum. Dis. 75, 210\u2013217 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jama.2012.156703","volume":"309","author":"DF Ransohoff","year":"2013","unstructured":"Ransohoff, D. F., Pignone, M. & Sox, H. C. How to decide whether a clinical practice guideline is trustworthy. JAMA 309, 139\u2013140 (2013).","journal-title":"JAMA"},{"key":"BFnrrheum2017126_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett, D. L., Rosenberg, W. M., Gray, J. A., Haynes, R. B. & Richardson, W. S. Evidence based medicine: what it is and what it isn't. BMJ 312, 71\u201372 (1996).","journal-title":"BMJ"},{"key":"BFnrrheum2017126_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1617","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306, 711\u2013720 (2011).","journal-title":"JAMA"},{"key":"BFnrrheum2017126_CR43","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand, V., Khanna, D., Singh, J. A., Forsythe, A. & Edwards, N. L. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J. Rheumatol 39, 1450\u20131457 (2012).","journal-title":"J. Rheumatol"},{"key":"BFnrrheum2017126_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M16-0461","volume":"166","author":"PG Shekelle","year":"2017","unstructured":"Shekelle, P. G. et al. Management of gout: a systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 166, 37\u201351 (2017).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2017126_CR45","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz, U. et al. Treat-to-target (T2T) recommendations for gout. Ann. Rheum. Dis. 76, 632\u2013638 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR46","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker, M. A. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 12, R63 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2017126_CR47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr.","year":"2008","unstructured":"Schumacher, H. R. Jr. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540\u20131548 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2017126_CR48","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450\u20132461 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"BFnrrheum2017126_CR49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/annrheumdis-2016-eular.2727","volume":"75","author":"KG Saag","year":"2016","unstructured":"Saag, K. G. et al. THU0495 Examination of serum uric acid (sUA) lowering and safety with extended treatment with lesinurad and allopurinol in subjects with gout [abstract]. Ann. Rheum. Dis. 75 (Suppl. 2), 371 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 2","key":"BFnrrheum2017126_CR50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-eular.3140","volume":"75","author":"T Bardin","year":"2016","unstructured":"Bardin, T. et al. THU0537\u2005Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract]. Ann. Rheum. Dis. 75 (Suppl. 2), 386 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 10","key":"BFnrrheum2017126_CR51","first-page":"2352","volume":"67","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth, N. et al. Efficacy and safety in patients with tophaceous gout receiving lesinurad and febuxostat combination therapy: interim analysis of an extension study [abstract]. Arthritis Rheumatol. 67 (Suppl. 10), 2352 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2017126_CR52","doi-asserted-by":"publisher","unstructured":"Rai, S. K. et al. Trends in gout and rheumatoid arthritis hospitalizations in Canada from 2000\u20132011. Arthritis Care Res. (Hoboken) http:\/\/dx.doi.org\/10.1002\/acr.23012 (2016).","DOI":"10.1002\/acr.23012"},{"key":"BFnrrheum2017126_CR53","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2016.3517","volume":"315","author":"SY Lim","year":"2016","unstructured":"Lim, S. Y. et al. Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993\u20132011. JAMA 315, 2345\u20132347 (2016).","journal-title":"JAMA"},{"key":"BFnrrheum2017126_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","volume":"17","author":"JA Singh","year":"2015","unstructured":"Singh, J. A., Akhras, K. S. & Shiozawa, A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res. Ther. 17, 120 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2017126_CR55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon, D. H., Avorn, J., Levin, R. & Brookhart, M. A. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann. Rheum. Dis. 67, 609\u2013613 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR56","doi-asserted-by":"publisher","first-page":"e007214","DOI":"10.1136\/bmjopen-2014-007214","volume":"5","author":"R Jackson","year":"2015","unstructured":"Jackson, R. et al. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open 5, e007214 (2015).","journal-title":"BMJ Open"},{"key":"BFnrrheum2017126_CR57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.clinthera.2012.01.020","volume":"34","author":"H Park","year":"2012","unstructured":"Park, H., Rascati, K. L., Prasla, K. & McBayne, T. Evaluation of health care costs and utilization patterns for patients with gout. Clin. Ther. 34, 640\u2013652 (2012).","journal-title":"Clin. Ther."},{"key":"BFnrrheum2017126_CR58","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1185\/03007990903017966","volume":"25","author":"R Halpern","year":"2009","unstructured":"Halpern, R., Mody, R. R., Fuldeore, M. J., Patel, P. A. & Mikuls, T. R. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr. Med. Res. Opin. 25, 1711\u20131719 (2009).","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnrrheum2017126_CR59","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3899\/jrheum.150310","volume":"42","author":"PC Robinson","year":"2015","unstructured":"Robinson, P. C., Taylor, W. J. & Dalbeth, N. An observational study of gout prevalence and quality of care in a national australian general practice population. J. Rheumatol 42, 1702\u20131707 (2015).","journal-title":"J. Rheumatol"},{"key":"BFnrrheum2017126_CR60","doi-asserted-by":"publisher","first-page":"617","DOI":"10.7326\/M14-0227","volume":"161","author":"E Jutkowitz","year":"2014","unstructured":"Jutkowitz, E., Choi, H. K., Pizzi, L. T. & Kuntz, K. M. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann. Intern. Med. 161, 617\u2013626 (2014).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2017126_CR61","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2013-203226","volume":"72","author":"F Liot\u00e9","year":"2013","unstructured":"Liot\u00e9, F. & Choi, H. Managing gout needs more than drugs: 'Il faut le savoir-faire, l'art et la mani\u00e8re'. Ann. Rheum. Dis. 72, 791\u2013793 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR62","unstructured":"Dalbeth, N. et al. Overall reduction in acute flares during treatment with febuxostat compared with placebo over 2 years in patients with early gout [abstract] (American College of Rheumatology, 2016)."},{"issue":"Suppl. 2","key":"BFnrrheum2017126_CR63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/annrheumdis-2017-eular.5006","volume":"76","author":"M Doherty","year":"2017","unstructured":"Doherty, M. et al. OP0268 Nurse-led care versus general practitioner care of people with gout: a UK community-based randomised controlled trial [abstract]. Ann. Rheum. Dis. 76 (Suppl. 2), 167 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2017126_CR64","doi-asserted-by":"publisher","unstructured":"FitzGerald, J. D., Neogi, T. & Choi, H. K. Do not let gout apathy lead to gouty arthropathy. Arthritis Rheum. http:\/\/dx.doi.org\/10.1002\/art.40031 (2016).","DOI":"10.1002\/art.40031"},{"key":"BFnrrheum2017126_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7326\/M16-2401","volume":"166","author":"T Neogi","year":"2017","unstructured":"Neogi, T. & Mikuls, T. R. To treat or not to treat (to target) in gout. Ann. Intern. Med. 166, 71\u201372 (2017).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2017126_CR66","doi-asserted-by":"publisher","unstructured":"Singh, J. A. & Uhlig, T. Chasing crystals out of the body: will treat to serum urate target for gout help us get there? Ann. Rheum. Dis. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2016-210436 (2016).","DOI":"10.1136\/annrheumdis-2016-210436"},{"key":"BFnrrheum2017126_CR67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/M16-2426","volume":"166","author":"RM McLean","year":"2017","unstructured":"McLean, R. M. The long and winding road to clinical guidelines on the diagnosis and management of gout. Ann. Intern. Med. 166, 73\u201374 (2017).","journal-title":"Ann. Intern. Med."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.126","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2017.126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T21:38:15Z","timestamp":1750801095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2017.126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFnrrheum2017126"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2017.126","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]},"assertion":[{"value":"10 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.D., F.L., H.K.C. and R.T. were co-authors of the 2012 ACR guidelines for management of gout; M.D., F.L., A.K.S., P.R. and T.B. were co-authors of the 2016 updated EULAR evidence-based recommendations for the management of gout; and N.D., L.K.S. and M.D. were rheumatologist participants in the development of the 2014 international 3e Initiative recommendations for gout management. N.D. declares that she has received research grant support from AstraZeneca, has serverd as a speaker for Menarini, Ardea\/AstraZeneca, and Takeda, and acted as a consultant to AstraZeneca, Crealta, Cymabay, Fonterra, Pfizer, and Takeda. T.B. declares that he has received research support from AstraZeneca, Ipsen and Menarini and has served as a consultant and\/or speaker for Astellas, AstraZeneca, Cymabay, Grunenthal, Ipsen, Menarini, Novartis, Savient, Sobi and Takeda. M.D. declares that he has received research grant support from AstraZeneca and has served as a consultant to AstraZeneca, Grunenthal, Nordic Biosciences and Roche. F.L. has served as an adviser to Ardea, AstraZeneca, Grunenthal, Ipsen Pharma, Menarini and Novartis, received educational grants from Ardea, AstraZeneca, Grunenthal, Ipsen Pharma, Mayoly-Spindler, Menarini, Novartis, Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie and SOBI, and acted as speaker for AstraZeneca, Ipsen Pharma, Mayoly-Spindler, Menarini and Novartis. P.R. declares that he has acted as a consultant for AstraZeneca, Grunenthal, Ipsen Pharma\/Menarini and Savient. K.G.S. declares that he has served as a consultant and paid investigator for Ardea\/AstraZeneca, Horizon, SOBI and Takeda. L.K.S. declares that she has received research support from Ardea\/AstraZeneca and is a member of the Rheumatology Subcommittee of the Pharmaceutical Management Agency of New Zealand. A.K.S. declares that he has received honoraria and acted as a consultant for AstraZeneca, Menarini and SOBI in relation to gout studies. H.K.C. declares that he has served as a consultant for Ardea\/AstraZeneca and Takeda. R.T. declares that he has received research support from Ardea\/Astra-Zeneca and has served as a consultant for Aequus, Ardea\/AstraZeneca, CymaBay, Horizon, ProteoThera, Relburn, Revive, Selecta and SOBI. The G-CAN organization is supported, in an arms-length manner, by unrestricted grants from a number of pharmaceutical companies: AstraZeneca, CymaBay, Horizon, Selecta, SOBI, Takeda and Teijin. G-CAN members have demonstrated research expertise in gout, hyperuricaemia and\/or crystal arthropathy. A.K.S., F.L., H.K.C. and R.T. are G-CAN Board members.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}